RobertLouisFerrisMDPhD

Otolaryngology (ENT) • Pittsburgh, PA

Associate Professor of Otolaryngology, University Pittsburgh

Join to view full profile

Dr. Ferris is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ferris' full profile

Already have an account?

Office
200 Lothrop St
Ste 300
Pittsburgh, PA 15213
Phone+1 412-647-2100

Fax+1 412-621-1449

Education & Training

Johns Hopkins UniversityResidency, Otolaryngology - Head and Neck Surgery, 1996 - 2001
Johns Hopkins University/Bayview Medical CenterInternship, Transitional Year, 1995 - 1996
Johns Hopkins University School of MedicineClass of 1995

Certifications & Licensure

PA State Medical License 2001 - 2024
MD State Medical License 1996 - 2002
American Board of Otolaryngology - Head and Neck Surgery Otolaryngology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2011-2014
America's Top Doctors for Cancer Castle Connolly, 2010-2013
Fellow (FACS) American College of Surgeons
Fellow (FAAO-HNS) American Academy of Otolaryngology - Head and Neck Surgery
Join now to see all

Clinical Trials

Vaccine Therapy in Treating Patients With Head and Neck Cancer Start of enrollment: 2005 Sep 01
Completed
Phase 1
Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer Start of enrollment: 2007 Nov 01
Completed
Phase 2
Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions Start of enrollment: 2009 Aug 01
Completed
Phase 1
ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma Start of enrollment: 2011 Feb 01
Completed
Phase 2
A Phase Ib Trial of Concurrent Cetuximab (ERBITUX®) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY®) in Locally Advanced Head and Neck Cancer Start of enrollment: 2013 Apr 01
Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer Start of enrollment: 2014 Jan 22
Active, not recruiting
Phase 2
Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer Start of enrollment: 2013 Apr 09
Completed
Phase 1
SBRT With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated SCCHN Start of enrollment: 2013 Jul 03
Completed
Phase 2
Biological Vaccine: Semi-allogeneic Human Fibroblasts (MRC-5) Transfected With DNA Start of enrollment: 2016 Sep 01
Withdrawn
Phase 1
Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer Start of enrollment: 2018 Nov 16
Active, not recruiting
Phase 2
HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma Start of enrollment: 2020 Jul 06
Recruiting
Phase 2
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION) Start of enrollment: 2022 Oct 06
Recruiting
Phase 3
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Evaluation of radiomics as a predictor of efficacy and the tumor immune microenvironment in anti-PD-1 mAb treated recurrent/metastatic squamous cell carcinoma of the h...
Dan P Zandberg, Serafettin Zenkin, Murat Ak, Priyadarshini Mamindla, Vishal Peddagangireddy
Head & Neck. 2025-01-01
Association of Patient and Tumor Characteristics With Outcomes in Young Head and Neck Squamous Cell Carcinoma Patients.
Ronan W Hsieh, William E Gooding, Marci Nilsen, Mark Kubik, Zahra Kelly
Clinical Otolaryngology. 2025-01-01
1 citations
Impact of post-operative transoral robotic surgery hemorrhage on adjuvant treatment delays in patients with oropharyngeal squamous cell carcinoma.
Kelly E Daniels, Daniel R Awad, Shirley X Liu, Joseph Mocharnuk, Mark Kubik
Oral Oncology. 2024-12-01

Journal Articles

P16 as a Prognostic Biomarker for Nonoropharyngeal Squamous Cell Cancers: Avatar or Mirage?
Robert Ferris, MD, Journal of the National Cancer Institute
Staged Reconstruction (Delayed-Immediate) of the Maxillectomy Defect Using CAD/CAM Technology
Matthew M Hanasono, Mario G Solari, Robert L Ferris, Sebastian Brooke, Mark W Kubik, Matilda Dhima, Journal of Reconstructive Microsurgery

Lectures

Head and Neck Cancers. Integrating Immunotherapy Into Clinical Practice: Changes Over the Past Year (Part 2)
2018 ASCO Annual Meeting - Chicago, Illinois - 05/31/2018

Press Mentions

UPMC ‘S Cancer Center to Expand Clinical ResearchFebruary 7th, 2023
‘Outstanding’ Outcomes: Reduced Postop Radiation in HPV, Oropharynx CancerJanuary 5th, 2022
A New Post-Surgery Approach for Treating HPV-Related Throat Cancer Uses Less Radiation Safely and Spares the Majority of Patients from ChemotherapyDecember 21st, 2021
Join now to see all

Grant Support

Immune Activation By Cetuximab In Head And Neck Cancer PatientsNational Institute Of Dental &Craniofacial Research2010–2011
Chemokine Signals In Head And Neck Cancer ProgressionNational Cancer Institute2006–2010
Direct Measurement Rates Synthesis Turnover T-Lymphocytes Head/Neck CancerNational Center For Research Resources2005